Scientist II, Immunology

<h3>Who we are:</h3> <p>Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on delivering oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Kymera is also progressing degrader oncology programs that target undrugged or poorly drugged proteins to create new ways to fight cancer. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit&nbsp;<a href=""></a>&nbsp;or follow us on&nbsp;<a href="">X (formerly Twitter)</a>&nbsp;or&nbsp;<a href="">LinkedIn</a>.</p> <p>&nbsp;</p> <h3>How we work:</h3> <ul> <li><strong>PIONEER</strong>: We are courageous, resilient and rigorous in our mission to improve patients’ lives through our revolutionary degrader medicines.</li> <li><strong>COLLABORATE</strong>: We value trust + transparency from everyone. Our goals are shared, our decisions data-driven and our camaraderie genuine.</li> <li><strong>BELONG</strong>: We recognize our differences, inviting curiosity and inclusivity, so that our people are valued, seen, and heard.</li> </ul> <p>&nbsp;</p> <h3>How you’ll contribute:</h3> <p>In this role, you will be a critical member of our KT-621 program reporting to the Executive Director, Immunology. In preclinical studies, KT-621, Kymera’s first-in-class oral STAT6 degrader, demonstrated full inhibition of the IL-4/IL-13 pathway in all relevant human cell contexts with picomolar potency that was superior to dupilumab, and equivalent or superior efficacy to dupilumab in multiple preclinical efficacy studies. In addition, at low oral doses, KT-621 demonstrated near full in vivo STAT6 degradation and was well-tolerated in multiple preclinical toxicity studies. You will be responsible for developing and performing cellular and molecular assays to support mechanism of action studies, and enable hit finding and lead optimization in early to late-stage immunology discovery programs.&nbsp; You will be expected to excel in a dynamic environment, generate high quality data, analyze and communicate the results to project team members.&nbsp;&nbsp;</p> <ul> <li>Develop and optimize cellular assays including coculture assays for mechanistic investigation</li> <li>Characterize lead molecules&nbsp;<em>in vitro</em>&nbsp;in human and rodent primary immune and tissue cell types</li> <li>Maintain and build up cell inventory</li> <li>Support and maintain efficient lab operations for the Immunology team</li> </ul> <p>&nbsp;</p> <h3>What skills and experience you’ll bring:</h3> <ul> <li>PhD in Immunology with 2+ years of relevant experience post PhD</li> <li>Expertise in Th2 immunity and the related Bcell, and mast cell/basophil biology is a strong plus</li> <li>Extensive tissue culture experience with primary and immortalized cells. Skilled in genetic approaches such as CRISPR knockout/in and RNAi in cells</li> <li>Deep understanding of signal transduction and molecular mechanisms that lead to activation and inactivation of signaling pathways in cells</li> <li>Extensive experience with standard molecular biology techniques, including DNA constructs design, transfection with DNA constructs and transduction with viral expression systems, qRT-PCR, Western blotting, immunoprecipitation, MSD, Elisa etc.</li> <li>Ability to independently analyze and interpret experimental data with attention to detail in recording experimental data and presenting results to project teams.</li> <li>Willing to learn and capable of learning new areas as needed by project goals</li> <li>Understands the urgency to deliver and adapt to the fast pace at Kymera</li> </ul> <p>&nbsp;</p> <p>&nbsp;</p> <p><em>Kymera Therapeutics is proud to be an equal opportunity employer, seeking to create a welcoming and diverse environment.&nbsp; All applicants will receive consideration for employment without regard to</em> <em>race, color, religion, creed, gender, national origin, age, disability, veteran status, pregnancy, sex, marital status, gender expression or identity, genetic information, sexual orientation, citizenship, or any other legally protected class.</em></p>